MALAYSIAN PSORIASIS REGISTRY
PRELIMINARY REPORT OF A PILOT STUDY USING A NEWLY REVISED REGISTRY FORM

C C Chang, H B Gangaram, S H Hussein
Department of Dermatology, Kuala Lumpur Hospital, Jalan Pahang, 50586 Kuala Lumpur

INTRODUCTION
Psoriasis is a common chronic inflammatory disease affecting the skin, nails and joints with significant physical, psychological and economic impact. Thus far, published reports of successful clinical registries on psoriasis are few worldwide.

The Malaysian Psoriasis Registry (MPR) is the first skin disease clinical registry in Malaysia. Pioneer efforts were started in 1998 by a group of dermatologists under the umbrella body of Dermatological Society of Malaysia, and a preliminary report was published in August 2005.

With strong financial and technical support from the Ministry of Health and Clinical Research Centre, MPR was given a new lease of life in 2007. The registry case report form was extensively revised. A total of 10 government dermatological centres voluntarily participated in the pilot data collection.

RESULTS & DISCUSSION
This preliminary report contains the results and analysis of a three-month period from 1st Oct to 31st Dec 2007.

A total of 509 patients with psoriasis (80 new cases and 429 follow-up cases) were reported.

Male-to-female ratio: 1:2.61

Ethnic distribution: Malays 51.1%, Chinese 28.3%, Indians 17.3% and other ethnic groups 3.8% in the majority of patients (59.7%), the disease onset was during the second to fourth decade of life.

Overall mean age of onset was 32.9 (range 2 – 80 years). Females had slightly earlier onset compared to males (mean age of onset 30.2 yrs vs. 35 yrs, t=3.255, p=0.001).

21.2% of patients had at least one family member suffering from psoriasis. Positive family history seemed to be more common in patients with younger onset of disease (aged 40 and below): 24.8% vs. 13.9% (OR=2.05, 95%CI=1.24-3.39, p<0.01).

The majority of patients (57%) reported one or more factors which aggravated their psoriasis. (Figure 1)

The commonest clinical type of psoriasis was plaque psoriasis (80.9%). (Figure 2)

Figure 1: Aggravating factors of psoriasis

Figure 2: Clinical types of psoriasis

Psoriatic arthropathy occurred in 17.3% of patients. The commonest clinical pattern was oligo-/monocarcticular type (46.6%) (Figure 4)

Figure 4: Joint involvement in psoriasis patients

About two-third of patients (68%) had nail changes related to psoriasis.

In adult patients (age above 18 years), the mean body mass index (BMI) was 25.8

33.6% of adult patients were overweight (BMI 25 to 29.9), and 21.3% were obese (BMI 30 and above).

These figures are high compared to the corresponding figures of 20.7% and 5.6% in normal Malaysian population.

A number of patients had one or multiple concomitant diseases such as hypertension (21%), hyperlipidaemia (16.3%), diabetes mellitus (15.3%), and ischemic heart disease (9.4%)

Measurement of quality of life using DLQI was performed in 508 patients. The mean DLQI score was 8.08 ± 6.29 (Min 0, Max 29)

METHODOLOGY
The MPR is an ongoing systematic collection of data pertaining to patients who have psoriasis.

All patients who are clinically diagnosed to have psoriasis by a registered dermatologist or by a medical practitioner under the supervision of a dermatologist are included. Confirmation of diagnosis by histopathologic examination is optional. Patients whose diagnosis is in doubt are excluded.

The study involves collection of data on the patient’s first visit to the participating centre and thereafter every 6 months on follow-up visits.

The Case Report Form consists of a clinical data form and multilingual Dermatology Life Quality Index (DLQI) forms separately for adult and children.

CONCLUSION
This pilot study provides a great opportunity to evaluate the newly revised registry form, and provides an excellent starting point for what will be a large scale nationwide continuous data collection effort.

Apart from revealing several interesting findings about psoriasis, more importantly the study helped to identify short-comings in the implementation of this registry. Our next steps should focus on resolving these issues in order to ensure greater benefit and future success of the registry.

REFERENCES

ACKNOWLEDGEMENT
We would like to thank the Ministry of Health for financial support, the Clinical Research Centre for technical assistance and advice, as well as all doctors and staff of the participating dermatological centres who contributed to this registry.